The Uromigos

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

496 Episoden

Episode 530: ESMO 2026 Review
2.11.2026
1:00:29
Silke, Brian and Tom review exciting ESMO 2026 data in GU Oncology and more.
Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival
25.10.2026
30:34
Danny Heng joins the show to discuss his ESMO 2026 presentation of LITESPARK-011 and the OS data. Published today in Annals of Oncology!
Verpasse keine Episode von “The Uromigos” und abonniere ihn in der kostenlosen GetPodcast App.
Episode 528: ESMO 2026 - LITESPARK 012
25.10.2026
44:02
Martin Voss takes on the role of Host and interviews Brian and Tom about this phase 3 study of triplets in metastatic ccRCC. Published today in Annals of Oncology!
Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer
24.10.2026
38:18
Chris Sweeney discusses this ANZUP trial which adds more phase 3 data to the high risk prostate cancer space.
Episode 526: ESMO 2026 - The VOLGA trial in MIBC
24.10.2026
37:07
Michiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.
Episode 525: ESMO 2026 - PEACE-1 and CAPItello-281
24.10.2026
46:49
Karim Fizazi joins Brian and Tom to discuss two ESMO 2026 presentations of long-term follow up data in mHSPC
Episode 524: ESMO 2026 - JNJ-6143, a Novel RIPTAC in mCRPC
24.10.2026
16:09
Ben Garmezy discusses the phase 1 data of a novel mechanism in CRPC. This RIPTAC (Regulated Induced Proximity TargetingChimera) Molecule uses AR to enter the prostate cancer cell and inhibits BRD4 to interfere with cell transcription.
Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC
23.10.2026
35:33
Jon Chatzkel joins us after his ESMO 2026 presentation to discuss ctDNA results from the KEYNOTE 905 trial.
Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC
23.10.2026
24:24
Anders Ullen joins the show after his EMSO 2026 presentation looking at KN-905 for the period in which Cis-ineligible MIBC patients were randomized to immediate cystectomy vs neoadjuvant Pembro or EVP.
Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
23.10.2026
32:47
Rob Jones joins the show to discuss two phase 3 trials from ESMO 2026 which did not show benefit from chemotherapy + IO vs chemo in MIBC. We discuss the wider implications incorporating the NIAGARA data and in light of neo/adjuvant EVP.

Weitere Episoden

Hol dir die ganze Welt der Podcasts mit der kostenlosen GetPodcast App.

Abonniere alle deine Lieblingspodcasts, höre Episoden auch offline und erhalte passende Empfehlungen für Podcasts, die dich wirklich interessieren.

Ein Unternehmen von

The Uromigos

The Uromigos

496 Episoden

Episode 530: ESMO 2026 Review

Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival

Episode 528: ESMO 2026 - LITESPARK 012

Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer

Episode 526: ESMO 2026 - The VOLGA trial in MIBC

Episode 525: ESMO 2026 - PEACE-1 and CAPItello-281

Episode 524: ESMO 2026 - JNJ-6143, a Novel RIPTAC in mCRPC

Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC